Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Centralna Biblioteka Wojskowa Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaCentralna Biblioteka Wojskowa

Wyszukujesz frazę "Prostate cancer" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-15 z 51
Tytuł:
Survival outcome and prognostic factors in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with abiraterone acetate – real-world experience in Vietnam
Autorzy:
Do, Tu Anh
Nguyen, Thai Hoa Thi
Nguyen, Hau Xuan
Nguyen, Loi Dinh
Nguyen, Chu Van
Powiązania:
https://bibliotekanauki.pl/articles/40555372.pdf
Data publikacji:
2024-06-30
Wydawca:
Uniwersytet Rzeszowski. Wydawnictwo Uniwersytetu Rzeszowskiego
Tematy:
abiraterone acetate
metastatic castration-resistant prostate cancer
overall survival
real-world evidence
Opis:
Introduction and aim. In real life, metastatic castration-resistant prostate cancer patients (mCRPC) had more complex clinical presentation than patients in the COU-AA-302 trial. This study primarily aimed to describe the overall survival of chemotherapy-naive mCRPC treated with abiraterone acetate plus prednisone (AAP). Other relevant outcomes and baseline characteristics of these patients were also evaluated. Material and methods. This retrospective, observational study collected data from chemotherapy-naive mCRPC patients treated with AAP in Vietnam. Kaplan-Meier curves were used to estimate time to treatment failure (TTF), and overall survival (OS). The impact of baseline characteristics on OS was explored using univariate and multivariate Cox proportional hazard models. Results. Data from 65 eligible patients were analyzed. The rate of PSA response was 73.8%, median PSA PFS was 10.5 months (95% CI: 7.4–13.6), median TTF was 15 months (95% CI: 11.1–18.9), and median OS was 24.9 months (95% CI: 18.9–30.9). Shorter OS was significantly associated with a higher Gleason score (≥8), shorter time from ADT start to mCRPC (<12 months), visceral metastases, and <50% PSA decline (p<0.05). Conclusion. Abiraterone acetate plus prednisone is well tolerated and effective for chemotherapy-naive mCRPC patients in clinical practice. Moreover, Gleason score, visceral metastasis, time from ADT start to mCRPC, and PSA response are the independent indicators for predicting the OS of mCRPC patients in both univariate and multivariate analyses.
Źródło:
European Journal of Clinical and Experimental Medicine; 2024, 22, 2; 262-269
2544-2406
2544-1361
Pojawia się w:
European Journal of Clinical and Experimental Medicine
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Apalutamid for treatment of nonmetastatic castration-resistant prostate cancer - case study
Autorzy:
Sikora-Kupis, Bożena
Powiązania:
https://bibliotekanauki.pl/articles/22676707.pdf
Data publikacji:
2023-03-31
Wydawca:
Medical Education
Tematy:
non-metastatic castration-resistant prostate cancer
nmCRPC
androgen receptor targeted agents
ARTA
apalutamide
darolutamide
enzalutamide
Opis:
A special form of prostate cancer is non-metastatic castration-resistant prostate cancer. Patients with this form have rising prostate-specific antigen and castrate testosterone levels, with no radiological findings of metastatic disease on computed tomography and bone scan. The phase III trials demonstrated apalutamide, darolutamide or enzalutamide to be associated with a significantly longer median metastasis-free survival. The featured description presents one case of man with non-metastatic castration-resistant prostate cancer who was treated with apalutamide.
Źródło:
OncoReview; 2023, 13, 1; 6-8
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Apalutamide as a new option for postponing metastatic disease in hormone -resistant patients with biochemical recurrence in prostate cancer
Autorzy:
Dąbek, Bartosz
Powiązania:
https://bibliotekanauki.pl/articles/22676825.pdf
Data publikacji:
2023-04-04
Wydawca:
Medical Education
Tematy:
non-metastatic castration-resistant prostate cancer
apalutamide
Opis:
Treatment of non-metastatic castration-resistant prostate cancer is a radically new option for cancer patients. Novel anti-hormonal therapy not only improves metastasis free survival but overall survival times and positively impacts quality of life. This case shows how apalutamide lowered tPSA level and postponed metastatic disease.
Źródło:
OncoReview; 2023, 13, 1; 24-26
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Apalutamide as a therapeutic option in case of local failure in the nmCRPC
Autorzy:
Stankiewicz, Magdalena
Powiązania:
https://bibliotekanauki.pl/articles/22676730.pdf
Data publikacji:
2023-04-01
Wydawca:
Medical Education
Tematy:
prostate cancer
castration resistance
apalutamide
Opis:
Apalutamide is a non-steroidal selective androgen receptor inhibitor approved for the treatment of high-risk non-metastatic castration-resistant prostate cancer and metastatic hormone-sensitive prostate cancer. The paper describes a case of a patient diagnosed with prostate cancer with a long-term course of the disease. The patient was diagnosed with a non-metastatic castration-resistant stage 18 years after primary treatment. Systemic treatment with apalutamide was recommended. Initially, the treatment was carried out as part of the extended access to apalutamide program and from March 2022 as part of the B.56 drug program. The study presents the effectiveness and safety of the therapy in a 12-month follow-up period and discusses controversial aspects of the patient's previous treatments.
Źródło:
OncoReview; 2023, 13, 1; 13-19
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Apalutamide in the treatment of a patient with non-metastatic castration-resistant prostate cancer
Autorzy:
Dziura, Robert
Powiązania:
https://bibliotekanauki.pl/articles/22676763.pdf
Data publikacji:
2023-03-31
Wydawca:
Medical Education
Tematy:
prostate cancer
castration-resistant
androgen receptor inhibitor
Opis:
The treatment of patients with prostate cancer, who do not qualify for the radical therapy is based on the use of surgical or pharmacological castration methods. The effectiveness of the so-called androgen deprivation tends to decrease over time. Even in the absence of distant metastases on imaging studies, the resistance for the hormonal castration may be developed. At this moment, the use of new generation androgen receptor inhibitors may reduce the risk of metastases or death. The paper presents a case report of a patient with prostate cancer without distant metastases who started therapy with apalutamide at the moment of developing re-sistance to the pharmacological castration.
Źródło:
OncoReview; 2023, 13, 1; 20-23
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Apalutamide treatment of locally advanced prostate cancer
Autorzy:
Palasik, Maria
Powiązania:
https://bibliotekanauki.pl/articles/22676859.pdf
Data publikacji:
2023-03-31
Wydawca:
Medical Education
Tematy:
prostate cancer
castration resistance
hormonotherapy
apalutamide
Opis:
Prostate cancer is most commonly diagnosed cancer in men. The choice of treatment method depends on many factors: the patient’s age, other patient’s diseases, psychophysical status and expected survival time. Hormonotherapy plays very important role in patients with no possible radical treatment. New therapies apply in patients with castration-resistant metastatic prostate cancer. First registered drug in patients with biochemical progression without metastases is apalutamide.
Źródło:
OncoReview; 2023, 13, 1; 31-32
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Gene-occupation interactions: a review of the literature on bladder and prostate cancer
Autorzy:
Wieczorek, Edyta
Wolniakowska, Anna
Roszak, Joanna
Rodrigues, Robim M.
Vanhaecke, Tamara
Reszka, Edyta
Powiązania:
https://bibliotekanauki.pl/articles/2203023.pdf
Data publikacji:
2023-05-19
Wydawca:
Instytut Medycyny Pracy im. prof. dra Jerzego Nofera w Łodzi
Tematy:
bladder cancer
gene
genetic susceptibility
occupational exposure
prostate cancer
workplace
Opis:
Bladder cancer (BCa) and prostate cancer (PCa) are genitourinary cancers which constitute significant health problems in men and in which environmental factors play an important role. Understanding the genetic susceptibility to BCa or PCa and occupational exposure is paramount to improving cancer prevention and early detection. The aim of this review article was to address the scientific evidence on the genetic risk factors and occupational exposure associated with the occurrence of BCa and PCa. The authors identified relevant original articles that have been published between 1994 and 2023. Variations of the following search terms: “gene” and “occupational” combined with one of the following terms: “bladder cancer” or “prostate cancer” were applied for the search purpose. The authors found 342 publications of which 50 population studies met their requirements for gene-occupation interactions. In total, 34 full-text manuscripts were about BCa and 16 about PCa. These research examines the genes involved in detoxification processes of xenobiotics (glutathione S-transferase, N-acetyltransferase, cytochrome P450, UDP-glucuronosyltransferase), oxidative stress (glutathione peroxidase 1, manganese superoxide dismutase, catalase), altering DNA repair capacity (X-ray repair cross-complementing 1, base excision repair, nucleotide excision repair), tumour suppression (TP53 gene), and vitamin D pathway (vitamin D receptor gene). The role of genetic factors in the occupational exposure has not been conclusively established, but it appears the possibility of genetic involvement. Determination of environmentally responsive genes provides important mechanistic implications for the etiology of occupational cancers, and valuable input in occupational exposure limits set by taking genetic susceptibility into account. More genetic research is needed to corroborate these findings and assess their significance in the workplace. Med Pr. 2023;74(2):127–44
Źródło:
Medycyna Pracy; 2023, 74, 2; 127-144
0465-5893
2353-1339
Pojawia się w:
Medycyna Pracy
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Prostate cancer in an elderly patient with a history of comorbidities
Autorzy:
Stryczyńska-Mirocha, Adriana
Mirocha, Martyna
Powiązania:
https://bibliotekanauki.pl/articles/22676694.pdf
Data publikacji:
2023-03-31
Wydawca:
Medical Education
Tematy:
prostate cancer
hormone therapy
nmCRPC
apalutamide
Opis:
Prostate cancer is the most common cancer in men in Poland. The choice of treatment method depends on many factors, including the stage of the disease, the patient's age, life expectancy, the presence of comorbidities and the general condition of the patient. Hormone therapy is one of the basic methods of prostate cancer treatment, both in adjuvant and palliative treatment. Castration-resistant prostate cancer is an incurable disease. However, the introduction of new hormonal drugs to therapy significantly extended the survival time of patients with relatively low harmfulness of therapy.
Źródło:
OncoReview; 2023, 13, 1; 3-5
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Prostate cancer in clinical practice. First experiences with apalutamide within the context of therapeutic program B.56
Autorzy:
Trzebiński, Krzysztof
Powiązania:
https://bibliotekanauki.pl/articles/22676841.pdf
Data publikacji:
2023-04-01
Wydawca:
Medical Education
Tematy:
non-metastatic castration-resistant prostate cancer
apalutamide
androgen receptor inhibitor
Opis:
The article contains a case report of patient diagnosed with castration-resistant non-metastatic prostate cancer, treated with a novel androgen receptor inhibitor – apalutamide.
Źródło:
OncoReview; 2023, 13, 1; 27-30
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Obesity, Physical Activity and Prostate Cancer: An Overview
Autorzy:
Kruk, Joanna
Bernstein, Joshua
Aboul-Enein, Basil H.
Powiązania:
https://bibliotekanauki.pl/articles/2138482.pdf
Data publikacji:
2022
Wydawca:
Uniwersytet Szczeciński. Wydawnictwo Naukowe Uniwersytetu Szczecińskiego
Tematy:
Overweight
obesity
prostate cancer
inflammation
physical activity
Opis:
Obesity and a lack of sufficient physical activity (PA) are recognized as risk factors for most civilization diseases, including cancer. This study synthesized the current evidence evaluating the relationship between excess body weight and prostate cancer (PCa) in the relation to the disease risk, progression, and mortality, and identifies biological plausibility of the association. We also estimated the importance of PA in intentional body weight loss. Several electronic major databases to identify eligible articles were searched until March 2022. A total 22 observational articles, the literature on the underlying biological mechanisms, and the crucial evidence of a role of PA in body weight maintenance and reduction were reviewed. The available knowledge suggests that association between body mass index and PCa is conflicting. However, the most research consistently shown that overweight/obesity was associated with higher risk of high-grade PCa and dying of PCa. Overweight/obesity can promote high-grade PCa through increased levels of secreted adipokines, increased formation of proinflammatory agents, and reduced concentration of adiponectin, among others. Being obese may by also linked with a higher risk of mortality. Exercise can decrease these health consequences related with obesity and may be effective in reduction of PCa-specific mortality, however, there are relative few studies on PA and PCa prevention among obese individuals.
Źródło:
Central European Journal of Sport Sciences and Medicine; 2022, 38; 71-91
2300-9705
2353-2807
Pojawia się w:
Central European Journal of Sport Sciences and Medicine
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
The role of enzalutamide in the treatment of prostate cancer from the perspective of Polish oncologists
Autorzy:
Bal, Wiesław
Gajda, Maksymilian
Powiązania:
https://bibliotekanauki.pl/articles/2159010.pdf
Data publikacji:
2022-06-30
Wydawca:
Medical Education
Tematy:
enzalutamide
prostate cancer
hormonotherapy
anti-androgen
second-generation an-
Opis:
For several years, prostate cancer has remained the most common malignancy in male patients in Poland. A large number of patients combined with rising costs of therapy translate into a significant socio-economic burden. In a clinical oncologist’s practice, we usually deal with patients with advanced prostate cancer. Taking into account the poorer prognosis in advanced disease, development of new therapeutic options as well we their adequate selection is of paramount importance. Enzalutamide is one of the second-generation androgen axis inhibitors, which has the ability to overcome resistance to androgen deprivation therapy by inhibiting the androgen-DNA signalling on several levels. Its efficacy and safety had been proven in numerous phase II and phase III clinical studies and it has been registered by regulatory authorities in the United States and European Union in the treatment of mCRPC, mCSPC and nmCRPC. In this article selected issues related to the treatment of prostate cancer are discussed, with particular emphasis on the role of enzalutamide (including its mechanism of action, indications, efficacy and safety).
Źródło:
OncoReview; 2022, 12, 2; 45-49
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Abiraterone acetate - 10 clinically relevant facts
Autorzy:
Żołnierek, Jakub
Powiązania:
https://bibliotekanauki.pl/articles/2047213.pdf
Data publikacji:
2021-09-30
Wydawca:
Medical Education
Tematy:
prostate cancer
systemic therapy
hormone therapy
abiraterone acetate
Opis:
Prostate cancer is one of the most frequently diagnosed cancers in men. Number of newly diagnosed cases is increasing due to several factors and the most important ones seem to be: population ageing and more sensitive diagnostic procedures. Secondary – the higher efficacy of treatment with its influence on improving patients’ overall survival and the specific mechanism of action of drugs used in systemic therapy lead to growing population of men suffering from prostate cancer in general and, specifically – patients with castration resistance. It is hormone therapy to play the key role in systemic treatment of prostate cancer with increasing significance of novel drugs focused on inhibition of molecular signal transduction mediated by androgen receptor. Abiraterone acetate is the representative of this therapeutic class. The paper describes the most clinically relevant data regarding the drug.
Źródło:
OncoReview; 2021, 11, 3; 80-84
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Apalutamide - 10 clinically important facts
Autorzy:
Juszczak, Kajetan
Drewa, Tomasz
Powiązania:
https://bibliotekanauki.pl/articles/2047224.pdf
Data publikacji:
2021-09-30
Wydawca:
Medical Education
Tematy:
apalutamide
prostate cancer
nonmetastatic
metastatic
CRPC
CSPC
Opis:
Apalutamide belongs to the ARTA group. This drug is a new generation selective androgen receptor inhibitor. Patients with prostate cancer develop resistance to castration testosterone levels over time during hormone therapy. Therefore, it is necessary to consider additional therapeutic options based on drugs from the ARTA group. Apalutamide is used in the treatment of patients with non-metastatic as well as metastatic prostate cancer. This article presents the most important clinical facts about apalutamide.
Źródło:
OncoReview; 2021, 11, 3; 85-88
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Cardiovascular complications during the treatment of castration-resistant prostate cancer with the use of modern antiandrogens: abiraterone acetate and enzalutamide
Autorzy:
Grabysa, Radosław
Chmielewska, Agnieszka
Powiązania:
https://bibliotekanauki.pl/articles/2047222.pdf
Data publikacji:
2021-09-13
Wydawca:
Medical Education
Tematy:
abiraterone acetate
enzalutamide
castration resistant prostate cancer
cardiovascular
Opis:
Modern antiandrogens: abiraterone acetate (inhibitor of CYP17 cytochrome) and enzalutamide (irreversible inhibitor of androgen receptor) are the drugs that are increasingly often administered in treatment of castration-resistant prostate cancer. Despite their clinical efficacy, especially in terms of prolonged survival and improved quality of life of patients, they pose of problem for a practicing oncologist such as possible cardiovascular complications (particularly arterial hypertension), which may lead to the cessation of this form of therapy. This article provides a brief overview of the mechanisms responsible for the above complications, including practical recommendations in the event such complications arise. A simple scheme of action for control of cardiovascular risk factors has been presented, which can improve the prognosis in this population of patients.
Źródło:
OncoReview; 2021, 11, 3; 61-67
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Refiguracje męskości w „narracjach prostatycznych”
Prostatic Narratives and the Refigurations of Masculinity
Autorzy:
Śmieja, Wojciech
Powiązania:
https://bibliotekanauki.pl/articles/1203046.pdf
Data publikacji:
2021-03-23
Wydawca:
Wydawnictwo Uniwersytetu Śląskiego
Tematy:
prostate
cancer
masculinity
aging
gender
patography
prostata
nowotwór
męskość
starzenie się
patografia
Opis:
Jednym z najbardziej rozpowszechnionych rodzajów nowotworu jest dotykający wielu mężczyzn nowotwór prostaty. Jako dotykający nie tylko cielesności, ale także społecznej i kulturowej tożsamości mężczyzny długo pozostawał w sferze tabu, choć od czasu eseju Susan Sontag Choroba jako metafora dokonuje się w kulturze Zachodu stopniowa detabuizacja raka. W ostatnich latach obserwujemy uobecnianie się „dyskursu prostatycznego” przez jego literackie zapisy, kulturowe reprezentacje, akcje świadomościowe czy wreszcie publiczne debaty. Ten moment jest interesujący dla badacza‑literaturoznawcy: „dyskurs prostatyczny” analizować trzeba na przecięciu kilku relatywnie nowych subdyscyplin nauk humanistycznych i społecznych: krytycznych studiów nad mężczyznami i męskościami, age studies i dyskursu maladycznego.Sięgając do tych trzech obszarów, autor poddaje lekturze powieść Duch wychodzi Philipa Rotha, powieść L’ablation Tahara Ben Jellouna (I wyd. 2014, nietłumaczona), esej/dziennik Philippe’a Petita: Philosophie de la prostate (wyd. 2018, nietłumaczona).Na podstawie przeprowadzonych analiz autor formułuje wniosek, że dokonujące się na naszych oczach rozpoznanie prostaty jako ważnego obszaru męskiej cielesności może przyczynić się do znaczących przesunięć w rozumieniu kulturowych i społecznych konwencji męskości.
The prostate cancer is one of the most widespread types of cancers among men. The disease attacks not only the male’s body, but it deeply concerns men’s social and cultural identity. As such, this type of cancer has been tabooed and its influence on men’s identity was silenced, even if Susan’s Sontag influential essay Disease as Metaphore aimed at redefining and demythologizing cancer. Literary and cultural representations of prostate cancer, identity andawareness‑rising actions among men have created in recent years a kind of “prostatic discourse.” This moment has a particular significance for a literary scholar: the newly established discourse could be analyzed intersectionally with the use of different methodologies: critical studies on men and masculinities, age studies, and maladic studies.On the basis of these fields of research I’m going to analyze Philip Roth novel Exit Ghost, L’ablation by Tahar Ben Jelloun, Philippe Petit’s Philosophie de la prostate.In conclusion I argue that the “prostate discourse” establishes the prostate as an important part of men’s bodies. It leads to a further conclusion that this recognition could result in important shifts in our understanding of cultural and social conventions of masculinity.
Źródło:
Rana. Literatura, Doświadczenie, Tożsamość; 2021, 1 (3); 1-24
2719-5767
Pojawia się w:
Rana. Literatura, Doświadczenie, Tożsamość
Dostawca treści:
Biblioteka Nauki
Artykuł
Wyświetlanie 1-15 z 51

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies